UNASSIGNED: Maternal consumption of a @entity1386 diet significantly impacts the fetal environment and predisposes offspring to @entity28 and @entity209 during adulthood. We examined the effects of a @entity1386 diet during pregnancy and lactation on metabolic and inflammatory profiles and whether maternal supplementation with the anti-inflammatory lipid conjugated @entity4722 (CLA) could have beneficial effects on mothers and offspring. @entity35 were fed a control ( @entity1050 ; 10% kcal from fat), CLA (CLA; 10% kcal from fat, 1% total fat as CLA), @entity1386 ( @entity1386 ; 45% kcal from fat) or high fat with CLA (HFCLA; 45% kcal from fat, 1% total fat as CLA) diet ad libitum 10days prior to and throughout gestation and lactation. Dams and offspring were culled at either late gestation (fetal day 20, F20) or early postweaning (postnatal day 24, P24). CLA, @entity1386 and HFCLA dams were heavier than @entity1050 throughout gestation. Plasma concentrations of proinflammatory cytokines @entity3426 and @entity5 @entity39 factor-a were elevated in @entity1386 dams, with restoration in HFCLA dams. Male and female fetuses from @entity1386 dams were smaller at F20 but displayed catch-up growth and @entity73 at P24, which was reversed in HFCLA offspring. HFCLA dams at P24 were protected from @entity73 as compared to @entity1386 dams. Maternal CLA supplementation normalised inflammation associated with consumption of a @entity1386 diet and reversed associated programming of @entity209 in offspring. This demonstrates that there are critical windows of developmental plasticity in which the effects of an adverse early-life environment can be reversed by maternal dietary interventions.

Maternal supplementation with conjugated XXXX in the setting of diet-induced @entity28 normalises the inflammatory phenotype in mothers and reverses @entity209 and @entity73 in offspring.

@entity35 :: ('10116', 'Species') :: ['Sprague-Dawley rats'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour'] @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis'] @entity73 :: ('MESH:D003072', 'Disease') :: ['impaired insulin sensitivity'] @entity1050 :: ('MESH:D006223', 'Disease') :: ['CD'] @entity1386 :: ('MESH:D018205', 'Disease') :: ['HF', 'high-fat'] @entity3426 :: ('24494(Tax:10116)', 'Gene') :: ['interleukin-1b'] @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic dysfunction'] @entity4722 :: ('MESH:D019787', 'Chemical') :: ['linoleic acid']
@entity4722 :: (MESH:D019787,Chemical) :: ['linoleic acid']
